Statistics from Altmetric.com
Rituximab is an approved B-lymphocyte depleting agent for induction of remission in patients with granulomatosis with polyangiitis and microscopic polyangiitis.1 ,2 Unlike cyclophosphamide, rituximab is not known to interfere with fertility and appears to be a safe and effective alternative. Pregnancy outcomes after maternal exposure to rituximab have been described,3 primarily in women with lymphoma, rheumatoid arthritis and lupus, but little is known about the impact of rituximab exposure on fetal outcomes, and more specifically, fetal B-lymphocyte populations among women with vasculitis. We performed a retrospective analysis of women with vasculitis who received rituximab in our centre and who achieved pregnancy, and their resultant offspring.
While receiving rituximab, women were counselled extensively to avoid pregnancy. Urine levels of human chorionic gonadotropin were measured and negative before each dose. …